Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  omeprazole
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-17 of 17 for your search:
Start Over
Phase III Randomized Study of Photodynamic Therapy Using Porfimer Sodium for the Ablation of High Grade Dysplasia in Barrett's Esophagus
Phase: Phase III
Type: Prevention, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: QLT-PHO-BAR-01, NCI-V98-1398
Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: NCI, Other
Protocol IDs: CPPDM95-084, P30CA016672, MDA-CPPDM-95084, NCI-T95-0003D, CDR0000064361, T95-0003, NCT00002682
Antibiotic Therapy in Treating Patients With Low Grade Gastric Lymphoma
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Other
Protocol IDs: EORTC-20961, CRC-EORTC-20961, HOVON-33, NCT00003151
A Phase 2 Clinical Trial of the Safety and Effects of IRX-2 in Treating Patients With Operable Head and Neck Cancer
Phase: Phase II
Type: Treatment
Status: Completed
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: IRX-2 2005-A, NCT00210470
Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 26866138-CAN-1001, NCT00298779
Evaluate the Effects of Patupilone on the Pharmacokinetics of Midazolam and Omeprazole in Patients With Advanced Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CEPO906A2123, NCT00420615
A Pharmacokinetic Study of RO5185426 in Combination With a Drug Cocktail in Patients With Metastatic Melanoma
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: NP22676, NCT01001299
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2012-02916, CDR0000685426, CO09908, 8516, P30CA014520, U01CA062491, WCCC-CO-09908, NCT01218620
BAY73-4506 Probe Substrate Study
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 12434, NCT01287598
Drug-drug Interaction Study of Tivantinib (ARQ 197) With Omeprazole, S-warfarin, Caffeine, Midazolam, and Digoxin in Cancer Subjects
Phase: Phase I
Type: Biomarker/Laboratory analysis
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: ARQ197-A-U158, NCT01517399
Drug Interaction Study of SAR302503 in Patients With Solid Tumor
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: INT12497, U1111-1125-8930, NCT01585623
Pharmacokinetic Drug-drug Interaction Study of Dovitinib (TKI258) in Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CTKI258A2119, 2011-001489-16, NCT01596647
Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 to 55
Sponsor: Pharmaceutical / Industry
Protocol IDs: D5160C00010, NCT02224053
Helicobacter Pylori Eradication to Prevent Gastric Cancer
Phase: No phase specified
Type: Natural history/Epidemiology, Prevention
Status: Closed
Age: 30 to 59
Sponsor: Other
Protocol IDs: SMMU20100501, NCT01133951
Start Over